{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:41:28Z","timestamp":1776991288383,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"S & T Program of Hebei, China","award":["19277716D"],"award-info":[{"award-number":["19277716D"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research in Beijing, China","award":["2020-2-2033"],"award-info":[{"award-number":["2020-2-2033"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04809-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:29:10Z","timestamp":1773764950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced nodal staging by molecular detection of KLK3, FOLH1, and PCA3 in prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Si-qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pu-shen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-feng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"2","key":"4809_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362. https:\/\/doi.org\/10.1016\/j.eururo.2020.09.042.","journal-title":"Eur Urol"},{"key":"4809_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172792","author":"P Zaurito","year":"2025","unstructured":"Zaurito P, Cosenza A, Quarta L, Scilipoti P, Longoni M, Santangelo A, et al. A narrative review of treatment options for patients with node-positive disease after radical prostatectomy: current evidence and controversies. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17172792.","journal-title":"Cancers"},{"issue":"12","key":"4809_CR3","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1002\/1097-0142(20001215)89:12<2577::AID-CNCR10>3.0.CO;2-V","volume":"89","author":"SR Potter","year":"2000","unstructured":"Potter SR, Mangold LA, Shue MJ, Taylor DC, Lecksell KL, Epstein JI, et al. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer. 2000;89(12):2577\u201386.","journal-title":"Cancer"},{"issue":"6 Pt B","key":"4809_CR4","doi-asserted-by":"publisher","first-page":"E166","DOI":"10.1111\/j.1464-410X.2012.10928.x","volume":"110","author":"D Schilling","year":"2012","unstructured":"Schilling D, Hennenlotter J, Gakis G, Schwentner C, Kuehs U, Stenzl A, et al. Prospective assessment of histological serial sectioning of pelvic lymph nodes in prostate cancer: a cost-benefit analysis. BJU Int. 2012;110(6 Pt B):E166-171. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.10928.x.","journal-title":"BJU Int"},{"issue":"8","key":"4809_CR5","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.urolonc.2012.03.006","volume":"31","author":"RP Dorin","year":"2013","unstructured":"Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Urologic Oncology November. 2013;31(8):1441\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2012.03.006.","journal-title":"Urologic Oncology November"},{"key":"4809_CR6","doi-asserted-by":"publisher","unstructured":"Doescher J, Veit JA, Hoffmann TK. The 8th edition of the AJCC cancer staging manual\u202f: updates in otorhinolaryngology, head and neck surgery. HNO. 2017;65(12):956\u201361. https:\/\/doi.org\/10.1007\/s00106-017-0391-3.","DOI":"10.1007\/s00106-017-0391-3"},{"issue":"10","key":"4809_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-17-3771","volume":"24","author":"MM Heck","year":"2018","unstructured":"Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, et al. Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection. Clin Cancer Res. 2018;24(10):2342\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-3771.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"4809_CR8","first-page":"4662","volume":"63","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003;63(15):4662\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"4809_CR9","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/bju.15153","volume":"126","author":"PC Albertsen","year":"2020","unstructured":"Albertsen PC. Prostate cancer screening and treatment: where have we come from and where are we going? BJU Int. 2020;126(2):218\u201324. https:\/\/doi.org\/10.1111\/bju.15153.","journal-title":"BJU Int"},{"issue":"4","key":"4809_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335. https:\/\/doi.org\/10.1038\/nrurol.2016.26.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"4809_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.eururo.2013.02.007","volume":"66","author":"MM Heck","year":"2014","unstructured":"Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, et al. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study. Eur Urol 2014;66(2):222\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2013.02.007.","journal-title":"Eur Urol\u00a0"},{"issue":"3","key":"4809_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3233\/CBM-150461","volume":"15","author":"I Tsaur","year":"2015","unstructured":"Tsaur I, Hennenlotter J, Oppermann E, Munz M, Kuehs U, Stenzl A, et al. PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases. Cancer Biomark. 2015;15(3):311\u20136. https:\/\/doi.org\/10.3233\/CBM-150461.","journal-title":"Cancer Biomark"},{"issue":"17","key":"4809_CR13","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1158\/1078-0432.CCR-1004-03","volume":"10","author":"R Kurek","year":"2004","unstructured":"Kurek R, Nunez G, Tselis N, Konrad L, Martin T, Roeddiger S, et al. Prognostic value of combined \u2018triple\u2019-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res. 2004;10(17):5808\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-1004-03.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4809_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/jnci\/djaf012","volume":"117","author":"P Scilipoti","year":"2025","unstructured":"Scilipoti P, Garmo H, Gedeborg R, Robinson D, Stattin P, Westerberg M. Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based study. JNCI J Natl Cancer Inst. 2025;117(6):1142\u201350. https:\/\/doi.org\/10.1093\/jnci\/djaf012.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"4809_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","volume":"91","author":"L Cheng","year":"2001","unstructured":"Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91(1):66.","journal-title":"Cancer"},{"key":"4809_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.09.043","author":"A Briganti","year":"2009","unstructured":"Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer.\u00a0A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol. 2009. https:\/\/doi.org\/10.1016\/j.eururo.2008.09.043.","journal-title":"Eur Urol"},{"issue":"5 Pt 1","key":"4809_CR17","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1097\/01.ju.0000140912.45821.1d","volume":"172","author":"ME Allaf","year":"2004","unstructured":"Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol. 2004;172(5 Pt 1):1840\u20134. https:\/\/doi.org\/10.1097\/01.ju.0000140912.45821.1d.","journal-title":"J Urol"},{"issue":"6","key":"4809_CR18","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1055\/a-0856-6545","volume":"50","author":"A Maxeiner","year":"2019","unstructured":"Maxeiner A, Grevendieck A, Pross T, Rudl M, Arnold A, Stephan C, et al. Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. Aktuelle Urol. 2019;50(6):612\u20138. https:\/\/doi.org\/10.1055\/a-0856-6545.","journal-title":"Aktuelle Urol"},{"issue":"10","key":"4809_CR19","first-page":"787","volume":"42","author":"T Deguchi","year":"1996","unstructured":"Deguchi T, Yang M, Nishino Y, Ehara H, Takahashi Y, Kawata Y, et al. Molecular approach to detection of micrometastatic prostatic cancer cells in the lymph nodes and the bone marrow. Hinyokika kiyo Acta Urol Jpn. 1996;42(10):787\u201390.","journal-title":"Hinyokika kiyo Acta Urol Jpn"},{"issue":"11\u201312","key":"4809_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.prp.2004.09.008","volume":"200","author":"CJ Haas","year":"2005","unstructured":"Haas CJ, Wagner T, Wawroschek F, Arnholdt H. Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Pathol Res Pract. 2005;200(11\u201312):763\u201370. https:\/\/doi.org\/10.1016\/j.prp.2004.09.008.","journal-title":"Pathol Res Pract"},{"key":"4809_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.07.005","volume":"44","author":"BC \u00d6zdemir","year":"2022","unstructured":"\u00d6zdemir BC, Arnold N, Fleischmann A, Hensel J, Klima I, de Kruithof- Julio M, et al. Prediction of biochemical recurrence based on molecular detection of lymph node metastasis after radical prostatectomy. Eur Urol Open Sci. 2022;44:1\u201310. https:\/\/doi.org\/10.1016\/j.euros.2022.07.005.","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"4809_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.urolonc.2011.04.003","volume":"31","author":"Y Kusuda","year":"2013","unstructured":"Kusuda Y, Miyake H, Kurahashi T, Fujisawa M. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction. Urol Oncol. 2013;31(5):615\u201321. https:\/\/doi.org\/10.1016\/j.urolonc.2011.04.003.","journal-title":"Urol Oncol"},{"key":"4809_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cca.2018.10.036","volume":"488","author":"KPP Htoo","year":"2019","unstructured":"Htoo KPP, Yamkamon V, Yainoy S, Suksrichavalit T, Viseshsindh W, Eiamphungporn W. Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles. Clin Chim Acta. 2019;488:40\u20139. https:\/\/doi.org\/10.1016\/j.cca.2018.10.036.","journal-title":"Clin Chim Acta"},{"key":"4809_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70700-8","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006. https:\/\/doi.org\/10.1016\/S1470-2045(06)70700-8.","journal-title":"Lancet Oncol"},{"key":"4809_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.04.017","author":"F Abdollah","year":"2018","unstructured":"Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, Briganti A, et al. Impact of adjuvant radiotherapy in node-positive prostate cancer patients: The importance of patient selection. Eur Urol. 2018. https:\/\/doi.org\/10.1016\/j.eururo.2018.04.017.","journal-title":"Eur Urol"},{"issue":"2","key":"4809_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41391-020-00283-3","volume":"24","author":"L Lunger","year":"2021","unstructured":"Lunger L, Retz M, Bandur M, Souchay M, Vitzthum E, J\u00e4ger M, et al. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer Prostat Dis. 2021;24(2):362\u20139. https:\/\/doi.org\/10.1038\/s41391-020-00283-3.","journal-title":"Prostate Cancer Prostat Dis"},{"key":"4809_CR27","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.1c03950","author":"S Lovell","year":"2021","unstructured":"Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E, et al. A suite of activity-based probes to dissect the KLK activome in drug-resistant prostate cancer. J Am Chem Soc. 2021. https:\/\/doi.org\/10.1021\/jacs.1c03950.","journal-title":"J Am Chem Soc"},{"key":"4809_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.05.010","author":"E Efstathiou","year":"2019","unstructured":"Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, et al. Clinical and biological characterisation of localised high-risk prostate cancer: Results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol. 2019. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.010.","journal-title":"Eur Urol"},{"key":"4809_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.4578","author":"M-E Taplin","year":"2014","unstructured":"Taplin M-E, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/JCO.2013.53.4578.","journal-title":"J Clin Oncol"},{"key":"4809_CR30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0731","author":"NE Fleshner","year":"2023","unstructured":"Fleshner NE, Sayyid RK, Hansen AR, Chin JLK, Fernandes R, Winquist E, et al. Neoadjuvant cabazitaxel plus abiraterone\/leuprolide acetate in patients with high-risk prostate cancer: ACDC-RP phase II trial. Clin Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0731.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4809_CR31","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/cas.14745","volume":"112","author":"H Cho","year":"2021","unstructured":"Cho H, Chung JI, Kim J, Seo WI, Lee CH, Morgan TM, et al. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis. Cancer Sci. 2021;112(2):859\u201370. https:\/\/doi.org\/10.1111\/cas.14745.","journal-title":"Cancer Sci"},{"issue":"5","key":"4809_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051117","volume":"13","author":"S Engels","year":"2021","unstructured":"Engels S, Brautmeier L, Reinhardt L, Wasylow C, Hasselmann F, Henke RP, et al. Evaluation of fast molecular detection of lymph node metastases in prostate cancer patients using one-step nucleic acid amplification (OSNA). Cancers. 2021;13(5):1117. https:\/\/doi.org\/10.3390\/cancers13051117.","journal-title":"Cancers"},{"key":"4809_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coi.2018.04.003","volume":"53","author":"M S\u00e1inz-Jaspeado","year":"2018","unstructured":"S\u00e1inz-Jaspeado M, Claesson-Welsh L. Cytokines regulating lymphangiogenesis. Curr Opin Immunol. 2018;53:58\u201363. https:\/\/doi.org\/10.1016\/j.coi.2018.04.003.","journal-title":"Curr Opin Immunol"},{"key":"4809_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2016.08.008","volume":"461","author":"J Wang","year":"2016","unstructured":"Wang J, Huang Y, Zhang J, Wei Y, Mahoud S, Bakheet AMH, et al. Pathway-related molecules of VEGFC\/D-VEGFR3\/NRP2 axis in tumor lymphangiogenesis and lymphatic metastasis. Clin Chim Acta. 2016;461:165\u201371. https:\/\/doi.org\/10.1016\/j.cca.2016.08.008.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"4809_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/1878-0261.12092","volume":"11","author":"MC Karlsson","year":"2017","unstructured":"Karlsson MC, Gonzalez SF, Welin J, Fuxe J. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol. 2017;11(7):781\u201391. https:\/\/doi.org\/10.1002\/1878-0261.12092.","journal-title":"Mol Oncol"},{"issue":"2","key":"4809_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.euf.2017.05.013","volume":"5","author":"F Petitprez","year":"2019","unstructured":"Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucian\u00f2 R, et al. PD-L1 expression and CD8\u2009+\u2009T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus. 2019;5(2):192\u20136. https:\/\/doi.org\/10.1016\/j.euf.2017.05.013.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"4809_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen S, Zhu G, Yang Y, Wang F, Xiao Y-T, Zhang N, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23(1):87\u201398. https:\/\/doi.org\/10.1038\/s41556-020-00613-6.","journal-title":"Nat Cell Biol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04809-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:19:29Z","timestamp":1776989969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04809-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4809"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04809-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of Beijing Chaoyang Hospital, Capital Medical University, and was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All patients have signed informed consent forms allowing anonymous public publication of relevant case information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"636"}}